Quality of life and treatment satisfaction with conventional systemic therapy in patients with psoriasis vulgaris - an observational study.

• Conditions: L40.0; Psoriasis vulgaris

• Registration Number: DRKS00008721
• Lead Sponsor: niversitätsklinikum Heidelberg

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2015-10-19
• Study Completion: 2016-03-31
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Patients with plaque psoriasis who begin therapy with a conventional systemic drug (Apremilast, methotrexate or Fumaderm) at the Department of Dermatology at the University of Heidelberg.

Patients must be at least 18 years old and give their written consent for study participation.

Exclusion Criteria

Patients who are younger than 18 years of age, or are not fluent of the German language.
Furthermore, patients with psychiatric diagnoses are excluded.

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The aim of this study is to provide the quality of life, in the first 6 months of treatment, measured with the DLQI questionnaire and to compare these - in patients with conventional systemic therapies, with the approved drugs (Apremilast, methotrexate, Fumaderm).

Secondary Outcome Measures

Name	Time	Method
The aim of this study is it furthermore in the first 6 months of Treatment, to measure and compare treatment satisfaction with the TSQM questionnaire - in patients with conventional systemic therapies (Apremilast, MTX, Fumaderm)